Anemia Clinical Trial
— NIPPAOfficial title:
NIPPA: Non-Invasive Haemoglobin Measurement to Identify Preoperative Anaemia in Patients Scheduled for Elective Orthopaedic Surgery, a Single-centred Prospective Cohort Study.
| NCT number | NCT04247178 |
| Other study ID # | AC19147 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 31, 2020 |
| Est. completion date | March 17, 2020 |
| Verified date | November 2020 |
| Source | University of Edinburgh |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Approximately 20% of patients undergoing elective orthopaedic surgery are anaemic. When not identified and treated before surgery, this can lead to requiring blood transfusions, which brings additional expenses, time and inconvenience to the patient.It is recommended that preoperative assessment involves investigation and where possible, treatment of anaemia. The timescale between assessment and surgery makes it difficult to comply with guidelines without postponing surgery. This study will investigate adult patients scheduled for elective orthopaedic surgery, where a full blood count is to be taken as part of routine care. A paired non-invasive reading of their blood will be taken. It will be conducted at The Royal Infirmary, Edinburgh. This device is not in use within the department currently but has been given free of charge for the study. There are no restrictions placed on the device except that it is not accurate for measuring haemoglobin <8g.dL. Participant care will only be determined by results from the laboratory assay as per routine care, not the noninvasive device. The device is CE marked for haemoglobin determination. Masimo (manufacturer) have released results in the accuracy of their monitor but with very little other information, for example, study population or precision. This study aims to answer how accurate and precise non-invasive measurements are in patients scheduled for orthopaedic surgery (there are no studies with these results) and whether anaemia can be identified earlier in the patient pathway i.e. an anaemia screen at time of surgical listing, therefore leaving ample time for treatment and optimisation of care. The data from the study will not be shared with Masimo. There is ongoing work towards introducing and piloting a new pre-operative triage system where optimisable conditions e.g. anaemia are identified at the time of listing. This study would aid this work.
| Status | Completed |
| Enrollment | 166 |
| Est. completion date | March 17, 2020 |
| Est. primary completion date | March 17, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 16 Years to 80 Years |
| Eligibility | Inclusion Criteria: - able to provide informed consent - aged between 16-80 years old - scheduled for elective orthopaedic surgery - a full blood count (FBC) is to be taken as part of routine care Inclusion Criteria for healthy volunteers cohort: - able to provide informed consent - aged between 16-80 years old Exclusion Criteria: - Patients with haemoglobin disorders - Raynaud's disease (or any other condition affecting the blood supply to the digits). Exclusion Criteria for healthy volunteers cohort: - Patients with haemoglobin disorders - Raynaud's disease (or any other condition affecting the blood supply to the digits). |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Royal Infirmary of Edinburgh | Edinburgh | The City Of Edinburgh |
| Lead Sponsor | Collaborator |
|---|---|
| University of Edinburgh | NHS Lothian |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The accuracy of the non-invasive device | assessed by calculating the agreement between the results obtained from the gold standard laboratory assay and the non-invasive device | January to March 2020 | |
| Secondary | Correlation of the non-invasive device to the gold standard | Intraclass correlation coefficient | January to March 2020 | |
| Secondary | Correlation of the non-invasive device to the gold standard | Interclass correlation coefficient | January to March 2020 | |
| Secondary | Predictive value of the non-invasive device | sensitivity | January to March 2020 | |
| Secondary | Predictive value of the non-invasive device | specificity | January to March 2020 | |
| Secondary | Predictive value of the non-invasive device | positive predictive value | January to March 2020 | |
| Secondary | Predictive value of the non-invasive device | negative predictive value | January to March 2020 | |
| Secondary | Factors independently associated with bias | age in years | January to March 2020 | |
| Secondary | Factors independently associated with bias | sex (male or female) | January to March 2020 | |
| Secondary | Factors independently associated with bias | perfusion index measured by noninvasive device | January to March 2020 | |
| Secondary | Factors independently associated with bias | pleth variability index measured by noninvasive device low signal quality | January to March 2020 | |
| Secondary | Factors independently associated with bias | heart rate measured by noninvasive device low signal quality | January to March 2020 | |
| Secondary | Factors independently associated with bias | SpO2 (peripheral oxygen saturation) measured by noninvasive device low signal quality | January to March 2020 | |
| Secondary | Factors independently associated with bias | low signal quality measured by noninvasive device low signal quality | January to March 2020 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
| Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |